-
Something wrong with this record ?
Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres
O. Šušol, B. Hájková, H. Zelená, R. Hájek
Language English Country Great Britain
Document type Journal Article
PubMed
35076937
DOI
10.1111/bjh.18073
Knihovny.cz E-resources
- MeSH
- COVID-19 * prevention & control MeSH
- Hematologic Neoplasms * therapy MeSH
- Humans MeSH
- Antibodies, Viral MeSH
- SARS-CoV-2 MeSH
- Antibody Formation MeSH
- BNT162 Vaccine MeSH
- COVID-19 Vaccines MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.
Department of Haemato oncology University Hospital Ostrava Ostrava Czech Republic
Faculty of Medicine University of Ostrava Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018524
- 003
- CZ-PrNML
- 005
- 20220804134830.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.18073 $2 doi
- 035 __
- $a (PubMed)35076937
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Šušol, Ondrej $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000178205987
- 245 10
- $a Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres / $c O. Šušol, B. Hájková, H. Zelená, R. Hájek
- 520 9_
- $a We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.
- 650 _2
- $a protilátky virové $7 D000914
- 650 _2
- $a tvorba protilátek $7 D000917
- 650 _2
- $a vakcína BNT162 $7 D000090982
- 650 12
- $a COVID-19 $x prevence a kontrola $7 D000086382
- 650 _2
- $a vakcíny proti COVID-19 $7 D000086663
- 650 12
- $a hematologické nádory $x terapie $7 D019337
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hájková, Barbora $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Zelená, Hana $u Institute of Public Health, Ostrava, Czech Republic
- 700 1_
- $a Hájek, Roman $u Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 197, č. 3 (2022), s. 302-305
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35076937 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134824 $b ABA008
- 999 __
- $a ok $b bmc $g 1822220 $s 1169767
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 197 $c 3 $d 302-305 $e 20220228 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20220720
